Massachusetts [US], June 2 (ANI): Researchers discovered that 42 percent of patients with metastatic brain cancer benefited from the immune checkpoint inhibitor pembrolizumab in a phase 2 clinical study, with seven patients living for more than two years. The authors emphasise that these advantages must be balanced against the potential…Read More
Science News Study Finds How Immunotherapy for Brain Cancer Metastases Displays Clinical Benefit LatestLY
